PDF(Pubmed)
Abstract：
Choroidal neovascularization (CNV) is a common pathological feature of various eye diseases and an important cause of visual impairment in middle-aged and elderly patients. In previous studies, tetrahedral framework nucleic acids (tFNAs) showed good carrier performance. In this experiment, we developed microRNA-155-equipped tFNAs (T-155) and explored its biological effects on CNV. Based on the results of in-vitro experiments, T-155 could regulate macrophages into the antiangiogenic M1 type. Then, we injected T-155 into the vitreous of laser-induced CNV model mice and found that T-155 significantly reduced the size and area of CNV, inhibited blood vessel leakage. In summary, we prove that T-155 could regulate the inflammatory process of CNV by polarizing macrophages, thereby improving the symptoms of CNV. Thus, T-155 might become a new DNA-based drug with great potential for treating CNV.
摘要：
脉络膜新生血管(CNV)是多种眼部疾病的共同病理特征,是中老年患者视力损害的重要原因。在以往的研究中,四面体骨架核酸(tFNA)表现出良好的载体性能。在这个实验中,我们开发了配备microRNA-155的tFNA（T-155），并探索了其对CNV的生物学效应。根据体外实验的结果,T-155可以调节巨噬细胞进入抗血管生成M1型。然后，我们将T-155注射到激光诱导的CNV模型小鼠的玻璃体中，发现T-155显着减小了CNV的大小和面积，抑制血管渗漏。总之,我们证明T-155可以通过极化巨噬细胞调节CNV的炎症过程，从而改善CNV的症状。因此，T-155可能成为一种新的基于DNA的药物，具有治疗CNV的巨大潜力。
